You're asking about a chemical compound with a very specific name. Let's break down what this compound is and why it might be important for research:
**1. Chemical Structure and Name:**
* **2-(2-methoxyphenyl)-1-oxo-N-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-isoquinolinecarboxamide:** This is the full IUPAC name, which describes the compound's structure.
* **Structure Breakdown:** The name is a bit intimidating, but it tells us how the molecule is put together:
* **Isoquinoline:** This is a fundamental ring system with a nitrogen atom.
* **Carboxamide:** This indicates a -CONH2 group, often found in pharmaceuticals.
* **2-methoxyphenyl:** This is a benzene ring with a methoxy (-OCH3) group attached at position 2.
* **4-(2-pyridinyl)-1-piperazinyl:** This is a piperazine ring with a 2-pyridinyl group attached.
* **2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl:** This portion contains a ketone group (2-oxo) and is connected to the piperazine ring.
**2. Potential Significance in Research:**
The compound's complex structure suggests it could be a potential drug candidate, perhaps targeting a specific biological pathway or receptor.
**Important Considerations:**
* **Specific Research Area:** To understand the compound's importance, you'd need to know the specific research area it's related to. Is it being studied for its anti-cancer properties, its effects on neurotransmission, or something else entirely?
* **Clinical Trials:** It's crucial to emphasize that the compound's potential is just a theoretical possibility. It may not be proven safe or effective for human use, and it could be in early stages of research with no guarantees of success.
* **Chemical Synthesis:** The chemical synthesis and characterization of this compound would be a complex undertaking requiring expertise in organic chemistry and analytical techniques.
**How to Learn More:**
* **Scientific Databases:** You could try searching for this compound on scientific databases like PubChem, ChemSpider, or Reaxys. These databases may provide information about its synthesis, properties, and potential biological activity.
* **Research Publications:** A search on scholarly databases like PubMed or Google Scholar might reveal research papers that mention or study this compound.
**In Conclusion:** This compound is a complex molecule with a potentially significant role in research, but its exact importance depends on the specific research context. To learn more, you need to investigate the research area it belongs to and search for relevant publications and databases.
ID Source | ID |
---|---|
PubMed CID | 3237403 |
CHEMBL ID | 1531549 |
CHEBI ID | 112693 |
Synonym |
---|
MLS000094984 |
smr000030535 |
MLS000878899 |
CHEBI:112693 |
AKOS001759189 |
2-(2-methoxyphenyl)-1-oxo-n-[2-oxo-2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]isoquinoline-4-carboxamide |
HMS2763C07 |
CHEMBL1531549 |
2-(2-methoxyphenyl)-1-oxo-n-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-isoquinolinecarboxamide |
Q27192807 |
SR-01000543176-1 |
sr-01000543176 |
Class | Description |
---|---|
N-acyl-amino acid | A carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 4.8452 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
ClpP | Bacillus subtilis | Potency | 28.1838 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 22.3872 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 14.2191 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
DNA polymerase beta | Homo sapiens (human) | Potency | 0.2818 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 28.1838 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 0.7079 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 4.4668 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 4.4668 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 4.4668 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 7.7039 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
Integrin beta-3 | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Integrin alpha-IIb | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |